BUSINESS
Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President
Sunao Manabe, incoming president of Daiichi Sankyo, has expressed his eagerness to capture the top spot in Japan ethical drug sales in the near future by bolstering the company’s anticoagulant Lixiana (edoxaban) and other major products. “We want to be…
To read the full story
Related Article
- Daiichi Sankyo Taps EVP Manabe as Next President
February 1, 2017
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





